October 3rd 2024
Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it priority review.
September 20th 2024
September 19th 2024
September 18th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
A 72-Year-Old Man With Heavily Pretreated, Relapsed/Refractory Multiple Myeloma
March 30th 2021Sagar Lonial, MD, FACP, presents a case of a 72-year-old man with heavily pretreated relapsed/refractory multiple myeloma and discusses treatment options for patients with this diagnosis who have failed multiple prior lines of therapy.
Watch
Belantamab Mafodotin in Clinical Practice for Heavily Pretreated MM
March 29th 2021Sagar Lonial, MD, FACP, discusses the FDA’s recent accelerated approval of belantamab mafodotin for patients with triple-class refractory multiple myeloma (MM) and considers best practices for managing ocular toxicities.
Watch
Orca-T Reduces GVHD, Mortalities in Hematologic Malignancies
March 28th 2021Data presented during the 2021 Transplantation and Cellular Therapy Meetings showed that treatment with Orca-T achieved a significant reduction in cases of graft-versus-host disease, an impressive GVHD relapse-free survival rate, and a lack of treatment-related mortalities while demonstrating scalability potential.
Read More
FDA Approves Ide-Cel for Relapsed/Refractory Multiple Myeloma
March 27th 2021The FDA has approved idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.
Read More
The REACH2 Study in Steroid-Refractory Acute GVHD
March 22nd 2021Dr Michael Bishop, of the David and Etta Jonas Center for Cellular Therapy, University of Chicago, describes the rationale for the design of the phase 3 REACH2 trial in steroid-refractory acute graft-versus-host disease and provides perspective on important takeaways from data presented.
Watch
Steroid-Refractory Acute Graft-Versus-Host Disease Defined
March 22nd 2021Michael Bishop, MD, shares recommendations that can help hematologists/oncologists appropriately identify patients with steroid-refractory acute graft-versus-host disease and describes how his treatment approaches differ based on grade.
Watch
Clinical Benefit Demonstrated With Ublituximab Plus Ibrutinib in R/R CLL
March 15th 2021Patients with relapsed or refractory high-risk chronic lymphocytic leukemia achieved a statistically higher rate of overall response when the glycoengineered, type I anti-CD20 monoclonal antibody ublituximab was added to the Bruton’s tyrosine kinase inhibitor ibrutinib, according to results from the phase 3 GENUINE study.
Read More
FDA Postpones Approval Decision on Belumosudil for Chronic Graft-Versus-Host Disease
March 12th 2021The FDA has extended the review period for the New Drug Application for belumosudil, which is being considered as a potential treatment option for patients with chronic graft-versus-host disease.
Read More